Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Prior treatment

• Received chemotherapy, biologics, or small molecule therapy within 21 days or 5 half-lives, whichever is shorter
• Use of any non-approved or investigational agent ≤ 4 weeks prior to the first dose of study drug.
• Received last prior anti-CD38 monoclonal antibody treatment within 28 days before first planned dose of the study drug
• Current Grade > 1 toxicity, with the exception of Grade 2 peripheral neuropathy, alopecia, or toxicities from prior anti-tumor therapy that are considered irreversible
• Large-field radiotherapy within 28 days prior to Day 1 (radiation to a single site as concurrent therapy is allowed)
• Prior autologous stem cell transplant within 180 days prior to Day 1
• Prior allogeneic stem cell transplant

Other illness

• History of clinically significant primary amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia or myelodysplastic syndrome

Other

• Inability to comply with study and follow-up procedures

• Adults > 18 years at time of consent
• ECOG performance status of 0 or 1
• Relapsed and/or refractory multiple myeloma after ≥ 3 prior lines; Must have failed treatment with an IMiD, PI, and anti-CD38 therapy
• Measurable disease per the IMWG response criteria
• Adequate marrow and organ function without transfusion or growth factor support within 7 days prior to screening
• Willing and able to undergo bone marrow aspirate and biopsy per protocol